Original Paper

Urine Catalytic Iron and Neutrophil Gelatinase-Associated Lipocalin as Companion Early Markers of Acute Kidney Injury after Cardiac Surgery: A Prospective Pilot Study

Krittapoom Akrawinthewong^a Michael K. Shaw^b Joshua Kachner^a
Eugene O. Apostolov^c Alexie G. Basnakian^d Sudhir Shah^e
Jacqueline Tilak^{f, g} Peter A. McCullough^{f, g}

^aDepartment of Internal Medicine, St. John Hospital and Medical Center, Detroit, Mich.,

^bSt. John Macomb-Oakland Center, Warren, Mich., ^cDepartment of Pharmacology and Toxicology, and Department of Nephrology, Internal Medicine, University of Arkansas for Medical Sciences, ^dDNA Damage and Toxicology Core Center, and Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, and ^eDivision of Nephrology, Department of Medicine, Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, Ariz., and ^fProvidence Hospitals and Medical Centers, Southfield, Mich. and Novi, Mich., and ^gSt. John Providence Health System, Warren, Mich., USA

Key Words

Catalytic iron · Marker · Neutrophil gelatinase-associated lipocalin · Acute kidney injury · Heart surgery

Abstract

Background: Open heart surgery with cardiopulmonary bypass is recognized as a common cause of acute kidney injury (AKI). The conventional biomarker creatinine is not sensitive enough to detect AKI until a significant decline in renal filtration has occurred. Urine neutrophil gelatinase-associated lipocalin (NGAL), part of an acute response to the release of tissue iron from cells, is an early biomarker and a predictor of AKI in a variety of clinical settings. We sought to evaluate the relationship between urine catalytic iron (unbound iron) and NGAL over the course of AKI due to cardiac surgery. **Methods:** Fourteen patients who underwent open heart surgery had the following measured: serum creatinine (0, 12, 24, 48 and 72 h postoperatively), urine NGAL and urine catalytic iron (0, 8, 24 and 48 h postoperatively). Urine NGAL and urine catalytic iron were quantified by immunoassay and bleomycin-detectable iron assay, respectively. AKI was defined by the Acute Kidney Injury Network (AKIN) criteria.

Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FNKF
Consultant Cardiologist, Chief Academic and Scientific Officer
St. John Providence Health System, Providence Park Heart Institute
47601 Grand River Avenue, Suite B-125, Novi, MI 48374 (USA)
E-Mail peteramccullough@gmail.com

Results: Urine catalytic iron increased significantly ($p < 0.05$) within 8 h and peaked at 24 h postoperatively in patients who developed AKI ($n = 8$, baseline 101.96 ± 177.48 , peak 226.35 ± 238.23 nmol/l, $p = 0.006$), but not in non-AKI patients ($n = 6$, baseline 131.08 ± 116.21 , peak 163.99 ± 109.62 nmol/l, $p = 0.380$). Urine NGAL levels also peaked at 24 h with significant increase observed only in AKI patients: AKI – baseline 34.88 ± 26.47 , peak 65.50 ± 27.03 ng/ml, $p = 0.043$; non-AKI – baseline 59.33 ± 31.72 , peak 71.00 ± 31.76 ng/ml, $p = 0.100$. The correlation between baseline levels of urine catalytic iron and NGAL and peak levels of urine catalytic iron and NGAL was $r = 0.86$, $p < 0.0001$. **Conclusion:** Urine catalytic iron appears to rise and fall in concert with NGAL in patients undergoing cardiac surgery and may be indicative of early AKI. Future research into the role that catalytic iron plays in acute organ injury syndromes and its potential diagnostic and therapeutic implications is warranted.

Copyright © 2013 S. Karger AG, Basel

Introduction

Acute kidney injury (AKI) is a common complication in hospitalized patients and is associated with significant morbidity and mortality including increased length of hospitalization and poor clinical outcomes [1]. Data from a recent multinational multicenter study showed that cardiac surgery with cardiopulmonary bypass (CPB) is the second most common cause of AKI among hospitalized patients [2]. Because the pathophysiology is not well established and there is no effective prophylaxis, early detection may be a cornerstone in dealing with this critical condition over the next several years.

The use of creatinine as a biomarker for AKI is limited in that its level rises after kidney injury has already occurred. Moreover, the creatinine assay across laboratories has not been well standardized. Recently, data showed that 41.1% of patients with AKI would go undiagnosed by using serum creatinine alone [3]. A novel marker that rises earlier than creatinine could allow for prompt detection and interventions to retard the progression of AKI.

Proteomic analysis has uncovered a number of interesting proteins in plasma and urine responsible for ischemic renal injury [4, 5]. Among these, neutrophil gelatinase-associated lipocalin (NGAL) is a promising transport protein that has been vigorously tested in a variety of patient settings as a predictor for AKI and poor clinical outcome [6–8] and also as a detector of AKI up to 48 h earlier than serum creatinine [9]. Its role as a biomarker still needs more exploration in particular situations, i.e. when the baseline NGAL is elevated and when the results from NGAL and serum creatinine are found to be discordant [10, 11].

Interestingly, this 25-kDa lipocalin-2 is known to have a scavenging role for labile iron-siderophore to prevent bacterial growth [12]. This putative mechanism raises the possibility of catalytic iron for use as a biomarker for earlier detection of organ injury. Several models of AKI, i.e. rhabdomyolysis, cisplatin-induced kidney injury, etc. [13], revealed the robust role of catalytic iron in their pathophysiology. Furthermore, Ho et al. [14] recently reported proteomic evidence that hepcidin-25, which is a regulator of iron homeostasis, may be protective in CPB patients and this was confirmed by a study from Haase-Fielitz et al. [15] who investigated urine hepcidin-25 isoforms as an early indicator in those who will not develop AKI. Therefore, urine catalytic iron, which is readily bound by urine NGAL or if unbound is reabsorbed at the level of the thick ascending limb of Henle's loop (TAL) and cortical collecting tubule in human kidney [16], merits study as a marker of AKI.

To our knowledge, there has been no human study regarding the relationship between urine catalytic iron and NGAL measured in the same patients, at the same time in the setting of cardiac surgery. Thus, we report serial values of both measures in a small cohort of unselected individuals undergoing surgery requiring CPB.

Methods

Patient Population

All patients of at least 18 years of age undergoing elective coronary artery bypass grafting surgery and/or heart valve surgery with planned CPB at Providence Hospitals and Medical Centers were invited for participation in the study. A total of 14 patients enrolled into this pilot study. We excluded patients who had an estimated glomerular filtration rate (GFR) of less than 30 ml/min/1.73 m², underwent emergency surgery, were being treated for active infection (i.e. sepsis, endocarditis), or developed shock or hemodynamic compromise which required a vasopressor. Renal function was monitored up to 72 h postoperatively. Informed consent was obtained and this study was conducted in compliance with the Declaration of Helsinki.

Data Collection and Definition

Demographic and clinical data (table 1) were collected for baseline at the time of admission. Serum creatinine, urine NGAL and catalytic iron were collected for baseline 3 h before starting surgery.

AKI was defined by Acute Kidney Injury Network (AKIN) criteria: an elevation of serum creatinine of at least 0.3 mg/dl, an increase of 50% compared to baseline within 48 h or a reduction in urine output defined as <0.5 ml/kg/h for more than 6 h after open heart surgery.

Sampling and Biochemical Analysis

For serum creatinine, blood sampling was done at 12, 24, 48 and 72 h postoperatively due to the schedule of laboratory work. Urine samples (6 ml) were collected in biosampler tubes at 8, 24 and 48 h after open heart surgery and immediately placed on ice. Samples were centrifuged (1,500 rpm, 15 min, 4°C) to remove any sediment. Patient samples were aliquoted into 3 ml tubes and were frozen at –70°C until used for biomarker analysis.

NGAL levels were measured using a capture/detection enzyme-linked immunosorbent assay per manufacturer's instructions (Kamiya Biomedical, Seattle, Wash., USA) and samples were analyzed in triplicate (Assay Designs Inc.). An interassay and intra-assay coefficient of variation (CV) of less than 10% was accepted. Serum creatinine levels (mg/dl) were determined by the St. John Providence Health System clinical laboratory using colorimetric assay (Beckman Coulter Inc.). Intra-assay CV was 4.3%. A combined interassay and intra-assay CV of less than 10% was considered acceptable for results reporting. For CV results above an intra-assay CV of 10%, the test was repeated. Urine catalytic iron was measured by bleomycin-detectable iron assay which uses the principle of deoxyribonucleic acid degradation by bleomycin in the presence of catalytic iron [17]. All reagents were pretreated with chelex using polypropylene tubes in order to avoid external iron contamination. Urine NGAL and catalytic iron excretion were measured in nanograms per milliliters and nanomoles per liter, respectively.

Statistical Analysis

SPSS version 15.0 (SPSS Inc., Chicago, Ill., USA) was used for all statistical analyses. For non-parametric statistics, the Mann-Whitney U test was used to compare the AKI and non-AKI group for continuous variables, whereas Fisher's exact test was used for categorical variables due to the small number of subjects. Spearman's correlation was applied to correlate between urine catalytic iron and NGAL level. A p value of less than 0.05 was considered as statistical significant. All graphs were constructed by GraphPad Prism® version 5.0. Data are presented as mean ± SD.

Results

Patient Characteristics

Patients' demographics, intra-operative risks of AKI, co-morbidities and operative details are summarized in table 1. Eight of fourteen patients in this study were found to have AKI according to the AKIN criteria. There was no significant difference observed ($p > 0.05$) between the AKI and non-AKI group except for type of surgery and duration of CPB which were significantly associated with postoperative AKI.

Table 1. Characteristics and marker levels of patients undergoing open heart surgery compared between the AKI and non-AKI group

Variables	All patients (n = 14)		Total	p value
	AKI (n = 8)	non-AKI (n = 6)		
<i>Patient characteristics</i>				
Age, years	74.63±10.90	62.33±11.96	69.36±12.60	0.081
Race ¹ (African/White), n	4/4	3/3	12	0.704
Sex (female/male), n	4/4	4/2	12	0.627
<i>Underlying disease</i>				
Hypertension, n	8	4	12	0.165
Dyslipidemia, n	5	3	8	0.521
Diabetes, n	3	3	6	0.529
History of CKD ² , n	4	0	4	0.085
History of smoking, n	3	3	6	0.529
<i>Details of hospitalization</i>				
Baseline hemoglobin ³ , g/dl	10.16±1.39	11.22±2.04	10.65±1.74	0.534
Blood transfusion ⁴ , units	1.00±0.00	1.60±0.89	1.30±0.67	0.310
Duration of surgery, min	310.88±149.76	343.17±102.72	324.71±128.10	0.573
Timing of on-pump ⁵ , min	121.88±67.37	25.33±39.86	80.50±74.25	0.012*
Cardiac catheterization ⁶ , h	10.50±19.70	8.00±19.60	9.43±18.93	0.852
Left ventricular ejection fraction before operation, %	46.25±8.35	45.00±16.58	45.77±11.52	0.943
Vasopressor use ⁷ , n	2	2	4	0.733
Length of stay, days	12.50±7.29	8.33±2.66	10.71±5.99	0.414
Total dose of diuretics ⁸ , mg	70.00±28.28	73.33±30.11	71.42±27.97	0.852
Coronary artery bypass graft surgery, n	7	1	8	0.026*
Heart valve surgery, n	1	5	6	
<i>Level of markers</i>				
Creatinine, mg/dl				
At baseline Cr	1.14±0.50	1.03±0.14	1.09±0.38	0.142
At 12 h postoperatively	1.44±0.41	0.98±0.24	1.24±0.41	0.029*
At 24 h postoperatively	1.63±0.68	0.95±0.22	1.33±0.59	0.008*
At 48 h postoperatively	1.75±1.06	0.93±0.19	1.40±0.89	0.043*
At 72 h postoperatively	1.98±0.84	0.88±0.21	1.51±0.85	0.005*
GFR, ml/min/1.73 m ²				
GFR ₀	49.25±31.87	62.09±33.14	53.32±35.41	0.037*
GFR ₁₂	33.02±29.58	39.02±47.82	35.26±40.01	0.634
GFR ₂₄	34.27±23.02	40.68±46.36	37.13±35.28	0.847
GFR ₄₈	32.75±24.96	41.34±47.93	35.33±34.58	0.847
GFR ₇₂	38.98±30.06	47.96±55.80	42.54±41.57	0.852
NGAL, ng/ml				
At baseline	34.88±26.47	59.33±31.72	45.36±30.36	0.142
At 8 h postoperatively	59.67±23.14	64.50±28.18	60.21±33.28	0.345
At 24 h postoperatively	65.50±27.03	71.00±31.76	67.86±28.10	0.950
At 48 h postoperatively	44.38±26.80	50.83±32.49	47.14±28.35	0.852
Catalytic iron, nmol/l				
At baseline	101.96±177.48	131.08±116.21	108.05±152.62	0.573
At 8 h postoperatively	159.90±126.16	121.86±99.99	135.73±127.53	0.755
At 24 h postoperatively	226.35±238.23	163.99±109.62	191.56±196.53	0.755
At 48 h postoperatively	196.66±181.23	80.41±87.28	143.16±158.51	0.081

(For footnote see next page.)

Fig. 1. Time trend for urine catalytic iron and NGAL for all patients (n = 14).

Baseline Levels and Postoperative Changes of Serum Creatinine, Urine Catalytic Iron and NGAL

Overall excursions for urine catalytic iron and NGAL are shown in figure 1. Urine catalytic iron increased significantly ($p < 0.05$) within 8 h and peaked at 24 h postoperatively in patients who developed AKI (n = 8, baseline 101.96 ± 177.48 , peak 226.35 ± 238.23 nmol/l, $p = 0.006$), but not in non-AKI patients (n = 6, baseline 131.08 ± 116.21 , peak 163.99 ± 109.62 nmol/l, $p = 0.380$). Those changes also remained up to at least 48 h after surgery (fig. 2). Urine NGAL levels also peaked at 24 h with significant increase observed only in AKI patients: AKI – baseline 34.88 ± 26.47 , peak 65.50 ± 27.03 ng/ml, $p = 0.043$; non-AKI – baseline 59.33 ± 31.72 , peak 71.00 ± 31.76 ng/ml, $p = 0.100$. For all three markers, there was no significant difference found between the AKI and non-AKI group at baseline (table 1). For serum creatinine, the AKI group showed significant change compared with the non-AKI group at 12 h after the operation and this difference persisted at least 72 h postoperatively.

A total of 10 subjects underwent intra-operative blood transfusion. There were no differences at baseline, peak, or from baseline to peak in catalytic iron, NGAL, or serum creatinine (online suppl. material, see www.karger.com/doi/10.1159/000346815).

(Footnote to table 1.)

Values are given as mean $\pm$ SD, unless indicated otherwise. GFR was calculated by MDRD equation. CKD = Chronic kidney disease; Cr = creatinine.

¹ Race: there are only African-American and Caucasian people in this study.

² History of CKD: defined by the National Kidney Foundation (NKF) criteria.

³ Baseline hemoglobin: value at 24 h before operation.

⁴ Amount of blood transfusions since 24 h before operation until 48 h postoperatively (1 unit of red blood cells = 350 ml).

⁵ CPB pump duration: measured in minutes.

⁶ Prior diagnostic cardiac catheterization before the operation.

⁷ Number of subjects who used vasopressor (dopamine, dobutamine and norepinephrine).

⁸ Furosemide treatment within 72 h after the operation.

* p value < 0.05 , statistically significant.

Fig. 2. Postoperative change of urine NGAL, urine catalytic iron and serum creatinine according to the development of AKI (* $p < 0.05$ compared with baseline at time zero).

Fig. 3. Scatter plot of the pairs of 'baseline urine NGAL and baseline urine catalytic iron', also 'peak of urine NGAL and peak of urine catalytic iron' ($r = 0.86$, $p < 0.0001$; Spearman's correlation).

Correlation of Urine Catalytic Iron and NGAL

There was a graphical trend of urine catalytic iron and urine NGAL levels observed postoperatively (fig. 1). Using Spearman's correlation with matched data between urine catalytic iron and urine NGAL at both baseline and peak level, a strong correlation was observed between these two biomarkers (fig. 3; $r = 0.86$, $p < 0.0001$).

Discussion

In our prospective pilot study, the majority of recruited patients was elderly and had low GFR at baseline. The significant association between coronary artery bypass graft and duration of CPB with AKI was found here as in previous studies [18, 19]. Serum creatinine measurements showed that AKI persisted at least 72 h after surgery. As expected, urine catalytic iron in those that developed AKI remained elevated compared to baseline for at least 48 h postoperatively. The fact that there was no significant difference in urine NGAL and catalytic iron level between the AKI and non-AKI group is consistent with our very small sample size and the large known variation in NGAL levels [20].

In recent years, there has been a growing body of knowledge regarding novel biomarkers for AKI such as NGAL, hepcidin, alpha-1 microglobulin and fatty acid-binding proteins, pointing toward catalytic iron as an important player in the pathophysiology of AKI. NGAL is a well-known siderophore-binding lipocalin that is released in response to free iron in cytosol or the pericellular spaces of the kidney to promote intracellular iron accumulation [21]. Its role is to prevent intracellular iron depletion which is a mechanism for cellular apoptosis. Heparin, which is also expressed in apical tubular epithelium of the TAL and cortical collecting duct [22] and recognized as a central regulator of iron homeostasis [23], was found to be an early predictive marker to rule out AKI in CPB patients [15]. Alpha-1 microglobulin, which is a marker indicating proximal tubular injury, has the role in heme degradation that contributes to toxic renal injury by released free iron [24, 25]. Fatty acid-binding protein is also a high-affinity heme-binding protein that was found to be increased in relation to the patients who developed AKI after cardiac surgery [26]. Considering all of this supporting evidence, catalytic iron in urine, which is the product of the target organ that we are investigating, is a reasonable promising candidate for early biomarkers of AKI. Interestingly, free iron release is the earliest observed signal for the elevation of other biomarkers associated with AKI. This observation accentuates the rationale of urine catalytic iron being a measurable determinant of AKI.

The pathogenesis of AKI in cardiac surgery with CPB is still a conundrum [2, 27]. Poorly liganded iron can be released from the myocardium, rise as a result of hemolysis with CPB, and possibly be locally produced in the kidney as part of the pathophysiology of AKI. Possible explanations of how free iron causes AKI in this context include oxidative stress via the Haber-Weiss reaction and hemolysis due to pump use causing depletion of nitric oxide (NO). In patients undergoing CPB, there are elevations of markers of systemic inflammation [28–30] and significant hemolysis [18, 31, 32]. Old-stored red blood cell transfusion also potentially contributes free hemoglobin which has been found to scavenge NO [33]. Since NO is a potent vasodilator, depletion of NO causes vasoconstriction, exacerbating the poor tissue perfusion already present in the transient low-cardiac output state during the transition off the pump [21]. Moreover, heme release increases catalytic iron levels [34]. Those free iron ions catalyze the Haber-Weiss reaction under the acidic milieu caused by tissue hypoxia to generate hydroxyl radicals that injure renal cells. It has been known that a high concentration of ferrous (Fe^{2+}) iron exerts a cytotoxic effect, especially in the proximal tubule [35–38]. It stands to reason that decreasing urinary iron excretion could decrease the rate of kidney function deterioration [39, 40]. Those proposed mechanisms may explain a recent study which showed that the volume

of a red blood cell transfusion is independently associated with AKI in patients who underwent CPB-using cardiac surgery [41]. However, such findings were not observed in our study. There was no significant difference in the rise of catalytic iron and NGAL between blood-transfusion and non-blood-transfusion groups. Also, no correlation between the transfused blood volume and peak level of biomarkers was observed (see online suppl. material). Since there is no reported active secretion of free iron from renal tubules, there are three possibilities to explain how catalytic iron leaks into urine. First, there is the overspill mechanism from hemolysis combining with activated heme oxygenase-1, the heme catabolism enzyme, in hypoxic condition [42] overwhelming iron reabsorption at the TAL and collecting ducts [16]. Second, there is decreased reabsorption of iron in the tubules as AKI progresses. Third, there is elevated local release of free iron from mitochondria of damaged renal cells [43] occurring primarily in the proximal tubule and the TAL, where a high number of mitochondria are found [44]. Taken together, the existing evidence regarding the role of catalytic iron in AKI pathogenesis of cardiac surgery with CPB and iron leakage under such conditions strongly support urine catalytic iron as a potential early biomarker for AKI in open heart surgery patients.

This is the first study investigating urine catalytic iron and urine NGAL simultaneously in open heart surgery patients. Our study displays a correlation between urine catalytic iron and NGAL levels and indicates that monitoring urine catalytic iron serially from baseline to postoperative phase can potentially detect AKI earlier than using the conventional marker serum creatinine or the novel marker urine NGAL. Furthermore, a combination of these markers may allow clinicians to overcome the limits of each marker when used individually and more effectively identify AKI in cardiac surgery patients.

Our study has all the limitations of pilot studies with very small sample sizes. Urine output was not available in the postoperative phase, eliminating its potential use in diagnosing AKI using AKIN criteria; however, Prowle et al. [44] have suggested that only creatinine is often sufficient and thus obviating urine output criteria. Next, the earliest time of measurement of urine catalytic iron and NGAL postoperatively was 8 h, eliminating the possibility of earlier detection of a rise in these biomarkers. Also, our urinary markers were not adjusted for urinary dilution. Lastly, the serum catalytic iron was not measured, which could have been used to correlate with urine catalytic iron levels or to verify the proposed spillover effect of iron potentially released by the heart or from hemolysis as a contributor to AKI [45]. Although catalytic iron seems to be a key player in the common pathway of tissue injury, this finding should not be extrapolated into other clinical contexts associated with AKI due to the unique pathophysiology in each setting.

Our findings show that baseline and postoperative serial urine catalytic iron measurements are valuable indicators of AKI after open heart surgery. Urine catalytic iron levels are highly correlated with NGAL levels. Further research is warranted regarding urine catalytic iron and its relationship to AKI. Our findings suggest the possibility of iron chelation as an approach to prevent or lessen cardiac surgery-associated AKI.

Acknowledgements

We thank all nursing and technical staff at Providence Hospitals and Medical Centers and laboratorians at the University of Arkansas for Medical Sciences for their kindness to co-ordinate and assist for serial specimen collection and measurement.

Disclosure Statement

There are no competing interests.

References

- 1 Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol* 2005;16:3365–3370.
- 2 Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 2005;294:813–818.
- 3 Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 2009;54:1012–1024.
- 4 Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 2003;14:2534–2543.
- 5 Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. *J Biol Chem* 1998;273:4135–4142.
- 6 Schinstock CA, Semret MH, Wagner SJ, Borland TM, Bryant SC, Kashani KB, Larson TS, Lieske JC: Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. *Nephrol Dial Transplant* 2012, E-pub ahead of print.
- 7 Jeong TD, Kim S, Lee W, Song GW, Kim YK, Chun S, Lee SG, Min WK: Neutrophil gelatinase-associated lipocalin as an early biomarker of acute kidney injury in liver transplantation. *Clin Transplant* 2012, DOI: [10.1111/j.1399-0012.2012.01610.x](https://doi.org/10.1111/j.1399-0012.2012.01610.x), E-pub ahead of print.
- 8 Koyner JL, Garg AX, Coca SG, Sint K, Thiessen-Philbrook H, Patel UD, Shlipak MG, Parikh CR: Biomarkers predict progression of acute kidney injury after cardiac surgery. *J Am Soc Nephrol* 2012;23:905–914.
- 9 McCullough PA, El-Ghoroury M, Yamasaki H: Early detection of acute kidney injury with neutrophil gelatinase-associated lipocalin. *J Am Coll Cardiol* 2011;57:1762–1764.
- 10 McIlroy DR, Wagener G, Lee HT: Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. *Clin J Am Soc Nephrol* 2010;5:211–219.
- 11 Bolognani D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. *Clin J Am Soc Nephrol* 2009;4:337–344.
- 12 Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J: Dual action of neutrophil gelatinase-associated lipocalin. *J Am Soc Nephrol* 2007;18:407–413.
- 13 Shah SV, Rajapurkar MM, Baliga R: The role of catalytic iron in acute kidney injury. *Clin J Am Soc Nephrol* 2011;6:2329–2331.
- 14 Ho J, Reslerova M, Gali B, Gao A, Bestland J, Rush DN, Nickerson PW, Rigatto C: Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. *Clin J Am Soc Nephrol* 2011;6:2340–2346.
- 15 Haase-Fielitz A, Mertens PR, Plass M, Kuppe H, Hetzer R, Westerman M, Ostland V, Prowle JR, Bellomo R, Haase M: Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study. *Crit Care* 2011;15:R186.
- 16 Yang J, Mori K, Li JY, Barasch J: Iron, lipocalin, and kidney epithelia. *Am J Physiol Renal Physiol* 2003;285:F9–F18.
- 17 Loeff BG, Epema AH, Navis G, Ebels T, van Oeveren W, Henning RH: Off-pump coronary revascularization attenuates transient renal damage compared with on-pump coronary revascularization. *Chest* 2002;121:1190–1194.
- 18 Hirayama T, Herlitz H, Jonsson O, Roberts D: Deformability and electrolyte changes of erythrocytes in connection with open heart surgery. *Scand J Thorac Cardiovasc Surg* 1986;20:253–259.
- 19 McCullough PA, Williams FJ, Stivers DN, Cannon L, Dixon S, Alexander P, Runyan D, David S: Neutrophil gelatinase-associated lipocalin: a novel marker of contrast nephropathy risk. *Am J Nephrol* 2012;35:509–514.
- 20 Haase M, Bellomo R, Haase-Fielitz A: Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. *J Am Coll Cardiol* 2010;55:2024–2033.
- 21 Hamada Y, Fukagawa M: Is hepcidin the star player in iron metabolism in chronic kidney disease? *Kidney Int* 2009;75:873–874.
- 22 Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W: The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. *J Endocrinol* 2005;184:361–370.
- 23 Larsson J, Allhorn M, Kerstrom B: The lipocalin alpha(1)-microglobulin binds heme in different species. *Arch Biochem Biophys* 2004;432:196–204.
- 24 Bernard AM, Vyskocil AA, Mahieu P, Lauwerys RR: Assessment of urinary retinol-binding protein as an index of proximal tubular injury. *Clin Chem* 1987;33:775–779.
- 25 Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, Noiri E, Devarajan P: Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. *Kidney Int* 2008;73:465–472.
- 26 Bellomo R, Auriemma S, Fabbri A, D'Onofrio A, Katz N, McCullough PA, Ricci Z, Shaw A, Ronco C: The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). *Int J Artif Organs* 2008;31:166–178.

- 27 Menasche P: The systemic factor: the comparative roles of cardiopulmonary bypass and off-pump surgery in the genesis of patient injury during and following cardiac surgery. *Ann Thorac Surg* 2001;72:S2260–S2265; discussion S2265–S2266, S2267–S2270.
- 28 Gueret G, Lion F, Guriec N, Arvieux J, Dovergne A, Guennegan C, Bezon E, Baron R, Carre JL, Arvieux C: Acute renal dysfunction after cardiac surgery with cardiopulmonary bypass is associated with plasmatic IL6 increase. *Cytokine* 2009;45:92–98.
- 29 Vermeulen Windsant IC, Snoeijs MG, Hanssen SJ, Altintas S, Heijmans JH, Koeppel TA, Schurink GW, Buurman WA, Jacobs MJ: Hemolysis is associated with acute kidney injury during major aortic surgery. *Kidney Int* 2010;77:913–920.
- 30 Takami Y, Makinouchi K, Nakazawa T, Glueck J, Benkowski R, Nose Y: Effect of surface roughness on hemolysis in a pivot bearing supported Gyro centrifugal pump (C1E3). *Artif Organs* 1996;20:1155–1161.
- 31 Kanamori Y, Tanabe H, Shimono T, Tani K, Yada I, Yuasa H, Kusagawa M: The effects of administration of haptoglobin for hemolysis by extracorporeal circulation [in Japanese]. *Rinsho Kyobu Geka* 1989;9:463–467.
- 32 Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C, Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D, Kim-Shapiro DB, Gladwin MT: Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. *Circulation* 2011;124:465–476.
- 33 Gutteridge JM: Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides. *FEBS Lett* 1986;201:291–295.
- 34 Zager RA, Foerder CA: Effects of inorganic iron and myoglobin on in vitro proximal tubular lipid peroxidation and cytotoxicity. *J Clin Invest* 1992;89:989–995.
- 35 Zager RA, Schimpf BA, Bredl CR, Gmur DJ: Inorganic iron effects on in vitro hypoxic proximal renal tubular cell injury. *J Clin Invest* 1993;91:702–708.
- 36 Pardo-Mindan FJ, Diez J, Esparza N, Robledo C: Renal siderosis in patients with heart-valve prostheses: clinical implications. *Nephrol Dial Transplant* 1990;5:847–850.
- 37 Landing BH, Gonick HC, Nadorra RL, Hyman CB, Wells TR, Villarreal-Engelhardt G, Mersch J, Agness CL: Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. *Pediatr Pathol* 1989;9:479–500.
- 38 Anderson BF, Baker HM, Norris GE, Rice DW, Baker EN: Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 Å resolution. *J Mol Biol* 1989;209:711–734.
- 39 Hershko C, Graham G, Bates GW, Rachmilewitz EA: Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. *Br J Haematol* 1978;40:255–263.
- 40 Ponka P: Cellular iron metabolism. *Kidney Int Suppl* 1999;69:S2–S11.
- 41 Haase M, Bellomo R, Story D, Letis A, Klemz K, Matalanis G, Seevanayagam S, Dragun D, Seeliger E, Mertens PR, Haase-Fielitz A: Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. *Nephrol Dial Transplant* 2012;27:153–160.
- 42 Doi K, Suzuki Y, Nakao A, Fujita T, Noiri E: Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. *Kidney Int* 2004;65:1714–1723.
- 43 Takebayashi S, Jimi S, Segawa M, Takaki A: Mitochondrial DNA deletion of proximal tubules is the result of itai-itai disease. *Clin Exp Nephrol* 2003;7:18–26.
- 44 Prowle JR, Ostland V, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Bagshaw SM, Haase-Fielitz A, Haase M, Westerman M, Bellomo R: Greater increase in urinary hepcidin predicts protection from acute kidney injury after cardiopulmonary bypass. *Nephrol Dial Transplant* 2012;27:595–602.
- 45 Rajapurkar MM, Shah SV, Lele SS, Hegde UN, Lensing SY, Gohel K, Mukhopadhyay B, Gang S, Eigenbrodt ML: Association of catalytic iron with cardiovascular disease. *Am J Cardiol* 2012;109:438–442.